Clinical Trial Update: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial compared ABT-869 (linifanib) plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in advanced colorectal cancer; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Colon
• Adenocarcinoma of the Rectum
• Colorectal Cancer

Drugs mentioned

• ABT-869 (linifanib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Status: COMPLETED